Mercury Bio

Mercury Bio is a private, pre-clinical stage biotech company pioneering a novel approach to treating diseases driven by intracellular pathology. The company's proprietary MB-TIP™ platform combines engineered nanobodies (yEV™) and AI-informed design to deliver proteins, nanobodies, RNA, and small molecules across biological barriers and into cells, a significant challenge for existing biologics. With an initial focus on high-unmet-need neurodegenerative diseases, Mercury Bio aims to move beyond symptom management to potentially alter disease progression by targeting pathogenic proteins inside neurons. The company is advancing a pipeline across neurology, oncology, regenerative medicine, metabolic, and viral diseases, with pre-clinical validation from research partners like Vanderbilt University.

MB-TIP™ (Targeting Intracellular Pathologies) is a patented drug delivery platform designed to deliver engineered immunotherapeutics (proteins, nanobodies, RNA, small molecules) across biological barriers like the blood-brain barrier and directly into the cytoplasm of target cells. It integrates engineered nanobody delivery vehicles (yEV™), AI-informed ligand design, and engineered therapeutic payloads.

Mercury Bio competes in the crowded and challenging field of neurodegenerative disease therapeutics and advanced drug delivery. Competitors range from large pharma companies developing antibodies against extracellular amyloid or tau to other biotechs exploring gene therapies, ASOs, and alternative delivery modalities (e.g., focused ultrasound, Trojan horse approaches). Its unique claim is the combined ability to cross the BBB and achieve functional cytoplasmic delivery of large molecules.